![logo2](/ServeContent?url=http%3A%2F%2Fwww.heterocycles.jp%2Fclockss%2Fimg%2Fcycle.gif)
![logo2](/ServeContent?url=http%3A%2F%2Fwww.heterocycles.jp%2Fclockss%2Fimg%2Flogo_box.gif)
HETEROCYCLES
An International Journal for Reviews and Communications in Heterocyclic ChemistryWeb Edition ISSN: 1881-0942
Published online by The Japan Institute of Heterocyclic Chemistry
e-Journal
Full Text HTML
Received, 8th March, 2013, Accepted, 4th April, 2013, Published online, 8th April, 2013.
DOI: 10.3987/COM-13-12696
■ A Facile Green Synthesis and Anti-Cancer Activity of bis-Arylhydrazononitriles, Triazolo[5,1-c][1,2,4]triazine, and 1,3,4-Thiadiazolines
Sobhi M. Gomha, Khaled D. Khalil, Ali M. El-Zanaty, and Sayed M. Riyadh*
Department of Chemistry, Faculty of Science, Cairo University, Giza 12613, Egypt
Abstract
Coupling of 2-cyanoacetyl-1-methyl-1H-pyrrole (1) with diazonium salts of 1,4-benzenediamine (2), 2,6-dichlorobenzene-1,4-diamine (4), and benzidine (6) afforded bis-arylhydrazononitriles 3, 5, and 7, respectively. Also, coupling of 1 with [1,2,4]triazole-3-diazonium sulfate (8) gave the respective [1,2,4]triazolo[5,1-c][1,2,4]triazine derivative 11. On the other hands, treatment of 2-[(1-methyl-1H-pyrrol-2-yl)carbonyl]-3-mercapto-3-(phenylamino)acrylonitrile (12) with hydrazonoyl chlorides 13a-h in dioxane, in the presence of chitosan as eco-friendly heterogeneous basic catalyst, under microwave irradiation furnished 1,3,4-thiadiazolines 16a-h, incorporating pyrrole moiety. The anti-cancer activities of the synthesized products were determined against the colon carcinoma (HCT), human laryngeal carcinoma (Hep-2), human medulloblastoma (Daoy), human breast adenocarcinoma (MCF-7), and human colon adenocarcinoma (WiDr) cell lines.Arylazo compounds have multifarious industrial applications such as printing, electronic photography, liquid crystal displays, laser technology,1 and dye manufacture.2 Also, they are widely used in chromoionophores because they could exhibit substantial color changes observable by the naked eyes upon complexation with metal ions3 such as Ca+2, and Pb+2. Moreover, bis-arylazo compounds were reported to be used as a ratiometric and specific chromogenic sensor for Hg+2 in polar protic solvent.4 The rich chemistry of azo compounds is also associated with several important biological activities such as antimicrobial,5 antifungal,6 anticonvulsant,7 antioxidant, and antitumor.8 Recently, the synthesis of thiadiazoline derivatives9 has attracted considerable attention because these compounds have a wide range of biological properties. Thiadiazolines could be act as anthelmintics,10 antihypertensive,11 antitumor,12 analgesic,13 and antimicrobial agents.14 In view of the immense importance associated with arylazo and thiadiazolines and in continuation with our work related to the synthesis and evaluation the biological activities of aza-heterocycles,15-18 it was envisaged to undertake the synthesis and evaluation of the anti-cancer activity of a series of novel bis-arylazo and 1,3,4-thiadiazoline compounds. In this context, we could successfully utilized chitosan as efficient, eco-friendly heterogeneous basic catalyst under microwave irradiation to afford a novel environmentally benign route for synthesis of 1,3,4-thiadiazoline compounds.
2-Cyanoacetyl-1-methyl-1H-pyrrole (1),19 prepared via cyanoacetylation of 1-methyl-1H-pyrrole in the presence of catalytic amount of InCl3, was coupled with diazonium salts of appropriate aromatic amines [1,4-benzenediamine (2), 2,6-dichlorobenzene-1,4-diamine (4), and benzidine (6)] in molar ratio (2:1) in ethanol in the presence of sodium acetate to afford the respective bis-hydrazones [3, 5, and 7, respectively] (Scheme 1). The structures of the products were established on the basis of their elemental analyses and spectral data (IR, 1H NMR, 13C NMR, MS).
Hydrazones can be formulated in different possible tautomeric structures, namely keto-hydrazone (A), azo-enol (B), and CH-azo tautomer (C) (Figure 1). The 1H NMR spectra of the studied compounds showed signal in the region of δ = 13.83-13.92 ppm assignable to hydrazone proton (-CH=N-NH-).20 Signal at δ = 5.27 ppm,21 which is characteristic for the CH protons of CH-azo form, was not detected. Also, IR spectra did not reveal broad signal at 3434 cm-1, which is characteristic for OH of azo-enol form.22 These spectroscopic analyses allow to rule out the azo-enol form (B), CH-azo form (C), and confirm keto-hydrazone form (A) (Figure 1).
Keto-hydrazone tautomer (A) can be existed in two geometric structures (E and Z). IR spectra of compounds 3, 5, and 7 showed a shift of the CO bond stretching to lower wave number due to both conjugation with C=N and formation of a hydrogen bond with the NH group. Furthermore, the downfield shift of hydrazone proton signal (δ = 13.83-13.92 ppm) in 1H NMR is characteristic for the formation of an intramolecular hydrogen bond of the NH proton for structure (A). These results confirm only the presence of E- form.23
In continuation of our interest in the synthesis of bridged-head nitrogen heterocyclic systems,24 we have found that diazotized heterocyclic amines are excellent building blocks for the synthesis of the target compounds. Thus, coupling of 2-cyanoacetyl-1-methyl-1H-pyrrole (1) with [1,2,4]triazole-3-diazonium sulfate (8) in pyridine at 0-5 oC afforded 4-amino-3-[(1-methyl-1H-pyrrol-2-yl)carbonyl][1,2,4]triazolo[5,1-c][1,2,4]triazine (11)25 (Scheme 2). The structure of the isolated product was elaborated by its elemental analyses and spectral data. IR spectrum of 11 showed absorption bands at v = 3389, 3221 cm-1 assignable to NH2 group besides carbonyl absorption band at v = 1687 cm−1. Also, its 1H NMR spectrum revealed a singlet signal at δ 3.90 ppm (D2O-exchangeable) due to NH2 protons. The mechanism of formation of product 11 seems to start via initial coupling of diazonium salt on active methylene group in compound 1 to form the respective non-isolable hydrazone intermediate 9 which then underwent intramolecular cyclization followed by aromatization to give the isolated product 11 (cf. Scheme 2).
Next, our study was extended to explore a new synthetic approach to 1,3,4-thiadiazoline derivatives via green chemical techniques. Thus, stirring of 2-cyanoacetyl-1-methyl-1H-pyrrole (1) with phenyl isothiocyante in dimethylformamide, in the presence of potassium hydroxide, at room temperature gave the respective 2-[(1-methyl-1H-pyrrol-2-yl)carbonyl]-3-mercapto-3-(phenylamino)acrylonitrile (12) as previously mentioned26 (Scheme 3). Ttreatment of equimolar amounts of 12 with hydrazonoyl chlorides 13a-h in dioxane, in the presence of catalytic amount of chitosan (10% wt), under microwave irradiation resulted in the formation of 1,3,4-thiadiazolines 16a-h, with reaction times from 3 to 5 min at 300 W of power and temperatures of 150-160 oC (Scheme 3). The reaction products were easily obtained in high yields (90-94%). The spectroscopic data are consistent with structures 16a-h. These compounds showed the stretching bands of the C≡N group at 2188-2200 cm-1 while the carbonyl bands appeared at 1698-1705 cm-1. 1H NMR revealed a singlet signal at δ 3.47-3.78 ppm corresponding to (N-CH3) protons and another multiplet signals at δ 7.12-8.16 ppm corresponding to aromatic protons. In the 13C NMR spectrum the presence of a signal at δ 65.81-65.93 ppm, corresponding to vinylic carbon adjacent to nitrile group, and another signal at δ 164.30-165.42 ppm, corresponding to thiadiazoline C-2, confirms that such structure corresponds to 1,3,4-thiadiazol-2(3H)-ylidene derivatives.27
In Scheme 3, we postulate a plausible mechanism for such reactions. Firstly, nucleophilic displacement of (SH) group with concurrent elimination of hydrogen chloride afforded intermediates 14a-h. Intramolecular Michael type addition of (NH) group to vinylic double bond gave non-isolable Michael adducts 15a-h. Finally, elimination of aniline molecule from intermediates 15a-h gave the isolated products 16a-h.
The anti-cancer activities of the synthesized compounds 3, 5, 7, 11, 16a, 16b, 16f and 16h were determined against the colon carcinoma (HCT), human laryngeal carcinoma (Hep-2), human medulloblastoma (Daoy), human breast adenocarcinoma (MCF-7), and human colon adenocarcinoma (WiDr) cell lines. Data generated were used to plot a dose response curve of which the concentration of test compounds required to kill 50% of cell population (IC50) was determined. Cytotoxic activity was expressed as the mean IC50 of three independent experiments (Table 1).
The results revealed that, bis-arylhydrazononitriles 3, 5, and 7 have highest cytotoxicity values compared to triazolotriazine 11 and 1,3,4-thiadiazolines 16, which could be attributed to formation of azo-hydrazo isomers.28 Also, 1,3,4-thiadiazolines 16a, 16b, 16f, and 16h have higher cytotoxicity values than triazolotriazine 11, which could be attributed to size of heterocycles, number of nitrogen atoms in azoles and azines rings, and the nature of fusion of azoles or azines.28
Novel series of bis-arylhydrazononitriles, triazolotriazine, and 1,3,4-thiadiazolines, bearing pyrrole moiety were synthesized and evaluated for their anticancer activities. Most of the newly synthesized products revealed moderate anticancer activity against colon carcinoma (HCT), human laryngeal carcinoma (Hep-2), human medulloblastoma (Daoy), human breast adenocarcinoma (MCF-7), and human colon adenocarcinoma (WiDr) cell lines.
EXPERIMENTAL
General
Melting points were measured on a Gallenkamp melting point apparatus (Weiss-Gallenkamp, London, UK). IR spectra were recorded in potassium bromide discs on Pye Unicam SP 3300 and Shimadzu FTIR 8101 PC infrared spectrophotometers. NMR spectra were recorded on a Varian Mercury VX-300 NMR spectrometer operating at 400 MHz (1H NMR) or 100 MHz (13C NMR) and run in deuterated dimethylsulfoxide (DMSO-d6). Chemical shifts were related to that of the solvent. Mass spectra were recorded on a Shimadzu GCeMS-QP1000 EX mass spectrometer at 70 eV. Elemental analyses were measured by using a German made Elementar vario LIII CHNS analyzer. Microwave experiments were carried out using CEM Discover Labmate microwave apparatus (300 W with Chem. Driver Software). The cytotoxic evaluation of some selected examples was carried out in the Regional Center for Mycology and Biotechnology of Al-Azhar University, Cairo, Egypt. 2-Cyanoacetyl-1-methyl-1H-pyrrole (1)19 and hydrazonoyl halides29,30 were prepared as previously reported in the respective literature.
Coupling of 2-cyanoacetyl-1-methyl-1H-pyrrole (1) with the appropriate diazonium salt of aromatic amines
General procedure:
To a cold solution of 2-cyanoacetyl-1-methyl-1H-pyrrole (1) (0.296 g, 2 mmol) in EtOH (20 mL), containing sodium acetate trihydrate (0.138 g, 1 mmol), was added the appropriate diazonium salt of aromatic amines [1,4-benzenediamine (2) (0.108 g, 1 mmol), 2,6-dichlorobenzene-1,4-diamine (4) (0.177 g, 1 mmol), and benzidine (6) (0.184 g, 1 mmol)] portion wise over a period of 30 min. After stirring for further 2 h, at 0-5 oC, the reaction mixture was diluted with water and extracted with CHCl3. After evaporation of solvent, the crude product was purified by passing through column chromatography on silica gel using hexane/EtOAc (5:1) as an eluent.
N',N''-(1,4-Phenylene)bis[2-(1-methyl-1H-pyrrol-2-yl)-2-oxoacetohydrazonoyl cyanide] (3).
Red solid, (0.26 g, 61%), mp 230-232 oC; IR (KBr) υ 3281, 3154 (2NH), 2249, 2253 (2C≡N), 1691, 1687 (2C=O) cm-1; 1H NMR (DMSO-d6) δ = 3.82 (s, 6H, 2 N-CH3), 6.35-7.79 (m, 10H, Ar-H), 13.85 (s, 2H, D2O-exchangeable, 2NH) ppm; 13C NMR (DMSO-d6) δ = 32.62 (2CH3), 116.88 (2C≡N), 110.18, 121.72, 123.54, 129.43, 132.18, 148.22 (Ar-C), 178.12 (2C=O); MS, m/z (%) 426 (M+, 7), 400 (40), 318 (100). Anal. Calcd for C22H18N8O2 (426.16): C, 61.96; H, 4.25; N, 26.28. Found: C, 62.07; H, 4.38; N, 26.40%.
N',N''-(2,6-Dichloro-1,4-phenylene)bis[2-(1-methyl-1H-pyrrol-2-yl)-2-oxoacetohydrazonoyl cyanide] (5).
Dark red solid, (0.35 g, 71%), mp 249-251 oC; IR (KBr) υ 3265, 3158 (2NH), 2248, 2259 (2C≡N), 1698, 1685 (2C=O) cm-1; 1H NMR (DMSO-d6) δ = 3.80 (s, 6H, 2 N-CH3), 6.77-7.99 (m, 8H, Ar-H), 13.83 (s, 2H, D2O-exchangeable, 2NH) ppm; 13C NMR (DMSO-d6) δ = 32.52 (2CH3), 116.68 (2C≡N), 112.38, 122.21, 123.54, 123.98, 126.87, 129.43, 132.18, 136.37, 148.31 (Ar-C), 179.10 (2C=O); MS, m/z (%) 498 (M++4, 4), 496 (M++2, 12), 494 (M+, 40), 468 (30), 386 (100). Anal. Calcd for C22H16Cl2N8O2 (494.08): C, 53.35; H, 3.26; N, 22.62. Found: C, 53.27; H, 3.12; N, 22.43%.
N',N''-(Biphenyl-4,4'-diyl)bis[2-(1-methyl-1H-pyrrol-2-yl)-2-oxoacetohydrazonoyl cyanide] (7).
Red solid, (0.35 g, 70%), mp 205-207 oC; IR (KBr) υ 3251, 3119 (2NH), 2243, 2250 (2C≡N), 1693, 1685 (2C=O) cm-1; 1H NMR (DMSO-d6) δ = 3.85 (s, 6H, 2 N-CH3), 6.68-7.82 (m, 14H, Ar-H), 13.92 (s, 2H, D2O-exchangeable, 2NH) ppm; 13C NMR (DMSO-d6) δ = 33.12 (2CH3), 117.28 (2C≡N), 112.38, 120.54, 121.72, 123.54, 128.13, 129.41, 132.18, 142.55, 148.22 (Ar-C), 179.18 (2C=O); MS, m/z (%) 502 (M+, 20), 476 (40), 394 (100). Anal. Calcd for C28H22N8O2 (502.19): C, 66.92; H, 4.41; N, 22.30. Found: C, 67.07; H, 4.34; N, 22.42%.
Coupling of 2-cyanoacetyl-1-methyl-1H-pyrrole (1) with diazonium salt of heterocyclic amine.
To a cold solution of 2-cyanoacetyl-1-methyl-1H-pyrrole (1) (0.148 g, 1 mmol) in pyridine (20 mL), was added the diazonium salt of 3-amino-[1,2,4]triazole (8) (0.084 g, 1mmol), prepared according to literature procedures.31 After complete addition of the diazonium salt, the reaction mixture was stirred for a further 2 h in an ice bath, and then poured onto ice/HCl mixture. The solid precipitated was filtered off, washed with water, dried and crystallized from EtOH to give the respective product 11.
4-Amino-3-[(1-methyl-1H-pyrrol-2-yl)carbonyl][1,2,4]triazolo[5,1-c][1,2,4]triazine (11).
Yellow solid, (0.16 g, 66%), mp 154-156 oC; IR (KBr) υ 3389, 3221 (NH2), 1687 (C=O) cm-1; 1H NMR (DMSO-d6) δ 3.17 (s, 3H, N-CH3), 3.90 (br, 2H, D2O-exchangeable, NH2), 6.96-7.32 (m, 3H, Ar-H), 8.59 (s, 1H, triazole-H) ppm; MS, m/z (%) 243 (M+, 15), 163 (100), 135 (21). Anal. Calcd for C10H9N7O (243.09): C, 49.38; H, 3.73; N, 40.31. Found: C, 49.57; H, 3.88; N, 40.57%.
Synthesis of 2-[(1-methyl-1H-pyrrol-2-yl)carbonyl]-3-mercapto-3-(phenylamino)acrylonitrile (12).
To a stirred solution of potassium hydroxide (0.56 g, 10 mmol) in DMF (30 mL) was added 2-cyanoacetyl-1-methyl-1H-pyrrole (3) (1.48 g, 10 mmol). After stirring for 30 min, phenyl isothiocyanate (1.35 g, 10 mmol) was added to the resulting mixture. Stirring was continued overnight. The reaction mixture was acidified with HCl and the solid product was filtered off, washed with water and dried. Recrystallization from EtOH gave white solid (1.66 g, 70%), mp 156 oC; IR (KBr) υ 3246 (NH), 2201 (C≡N), 1705 (C=O) cm-1; 1H NMR (DMSO-d6) δ 3.45 (s, 3H, N-CH3), 7.15-7.59 (m, 8H, Ar-H), 10.23 (s, 1H, D2O-exchangeable, NH), 11.58 (s, 1H, SH) ppm; MS, m/z (%) 283 (M+, 7), 266 (17), 108 (100), 93 (85). Anal. Calcd for C15H13N3OS (283.08): C, 63.58; H, 4.62; N, 14.83; S, 11.32. Found: C, 63.81; H, 4.78; N, 14.99; S, 11.53%.
Reactions of 2-[(1-methyl-1H-pyrrol-2-yl)carbonyl]-3-mercapto-3-(phenylamino)acrylonitrile (12) with hydrazonoyl chlorides under microwave irradiation.
To a solution of 2-[(1-methyl-1H-pyrrol-2-yl)carbonyl]-3-mercapto-3-(phenylamino)acrylonitrile (12) (0.283 g, 1 mmol) and the appropriate hydrazonoyl chlorides 13a-h (1 mmol of each) in dioxane (10 mL) was added chitosan (0.1 g) at room temperature. The reaction mixture was irradiated under constant pressure (11.2 Bar, 150-160 oC) for 3-5 min at a power of 300 W. The hot solution was filtered to remove chitosan. After cooling, dil. HCl was added till pH became acidic, and the solid product was collected and recrystallized from EtOH or EtOH/DMF mixture to give products 16a-h. The physical constants together with the spectral data of 16a-h are listed below.
2-[(3,5-Diphenyl-1,3,4-thiadiazol-2(3H)-ylidene)]-3-(1-methyl-1H-pyrrol-2-yl)-3-oxopropanenitrile (16a).
Yellow solid (0.35 g, 91%), mp 272 oC; IR (KBr) υ 2188 (C≡N), 1703 (C=O) cm-1; 1H NMR (DMSO-d6) δ 3.47 (s, 3H, N-CH3), 7.12-7.86 (m, 13H, Ar-H) ppm; 13C NMR (DMSO-d6) δ 36.25, 65.82, 115.98, 119.35, 123.31, 126.12, 126.53, 127.90, 128.23, 129.16, 129.77, 130.04, 131.16, 133.42, 136.02, 156.77, 165.42, 178.13 ppm; MS, m/z (%) 384 (M+, 50), 194 (16), 108 (100), 77 (50), 53 (75). Anal. Calcd for C22H16N4OS (384.10): C, 68.73; H, 4.19; N, 14.57; S, 8.34. Found: C, 68.46; H, 4.12; N, 14.49; S, 8.19%.
2-[(5-Acetyl-3-phenyl-1,3,4-thiadiazol-2(3H)-ylidene)]-3-(1-methyl-1H-pyrrol-2-yl)-3-oxopropanenitrile (16b).
Yellow solid (0.32 g, 92%), mp 302 oC; IR (KBr) υ 2195 (C≡N), 1704, 1698 (2C=O) cm-1; 1H NMR (DMSO-d6) δ 2.68 (s, 3H, COCH3), 3.68 (s, 3H, N-CH3), 7.16-7.83 (m, 8H, Ar-H) ppm; 13C NMR (DMSO-d6) δ 26.73, 36.15, 65.86, 116.08, 119.11, 122.71, 125.82, 126.53, 127.93, 129.33, 133.12, 136.02, 159.78, 165.32, 178.33, 191.77 ppm; MS, m/z (%) 350 (M+, 20), 324 (16), 307 (70), 242 (100), 77 (50). Anal. Calcd for C18H14N4O2S (350.08): C, 61.70; H, 4.03; N, 15.99; S, 9.15. Found: C, 61.55; H, 3.82; N, 15.69; S, 9.03%.
2-[(5-Acetyl-3-(4-methylphenyl)-1,3,4-thiadiazol-2(3H)-ylidene)]-3-(1-methyl-1H-pyrrol-2-yl)-3-oxopropanenitrile (16c).
Yellow solid (0.33 g, 90%), mp 293 oC; IR (KBr) υ 2192 (C≡N), 1705, 1693 (2C=O) cm-1; 1H NMR (DMSO-d6) δ 2.39 (s, 3H, Ar-CH3), 2.64 (s, 3H, COCH3), 3.75 (s, 3H, N-CH3), 7.13-7.80 (m, 7H, Ar-H) ppm; MS, m/z (%) 364 (M+, 50), 338 (16), 321 (30), 256 (10), 108 (100). Anal. Calcd for C19H16N4O2S (364.10): C, 62.62; H, 4.43; N, 15.37; S, 8.80. Found: C, 62.35; H, 4.13; N, 15.60; S, 8.58%.
2-[(5-Acetyl-3-(4-chlorophenyl)-1,3,4-thiadiazol-2(3H)-ylidene)]-3-(1-methyl-1H-pyrrol-2-yl)-3-oxopropanenitrile (16d).
Yellow solid (0.35 g, 90%), mp 237 oC; IR (KBr) υ 2194 (C≡N), 1704, 1695 (2C=O) cm-1; 1H NMR (DMSO-d6) δ 2.67 (s, 3H, COCH3), 3.69 (s, 3H, N-CH3), 7.18-7.89 (m, 7H, Ar-H) ppm; MS, m/z (%) 386 (M++2, 7), 384 (M+, 25), 341 (16), 276 (40), 108 (100), 53 (50). Anal. Calcd for C18H13ClN4O2S (384.04): C, 56.18; H, 3.40; N, 14.56; S, 8.33. Found: C, 56.37; H, 3.53; N, 14.68; S, 8.51%.
2-[(5-Acetyl-3-(4-bromophenyl)-1,3,4-thiadiazol-2(3H)-ylidene)]-3-(1-methyl-1H-pyrrol-2-yl)-3-oxopropanenitrile (16e).
Yellow solid (0.39 g, 91%), mp 249 oC; IR (KBr) υ 2193 (C≡N), 1705, 1692 (2C=O) cm-1; 1H NMR (DMSO-d6) δ 2.63 (s, 3H, COCH3), 3.66 (s, 3H, N-CH3), 7.15-7.78 (m, 7H, Ar-H) ppm; MS, m/z (%) 430 (M++2, 20), 428 (M+, 22), 385 (40), 319 (50), 108 (100), 53 (50). Anal. Calcd for C18H13BrN4O2S (427.99): C, 50.36; H, 3.05; N, 13.05; S, 7.47. Found: C, 50.18; H, 3.17; N, 13.18; S, 7.61%.
Ethyl 5-[1-cyano-2-(1-methyl-1H-pyrrol-2-yl)-2-oxoethylidene)]-4-phenyl-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate (16f).
Yellow solid (0.35 g, 93%), mp 218 oC; IR (KBr) υ 2200 (C≡N), 1714, 1698 (2C=O) cm-1; 1H NMR (DMSO-d6) δ 1.32 (t, 3H, CH2CH3), 3.74 (s, 3H, N-CH3), 4.53 (q, 2H, CH2CH3), 7.17-7.81 (m, 8H, Ar-H) ppm; 13C NMR (DMSO-d6) δ 16.73, 36.11, 58.31, 65.93, 115.98, 119.43, 122.78, 124.82, 126.76, 128.13, 130.13, 132.98, 136.11, 159.88, 164.30, 178.33, 190.77 ppm; MS, m/z (%) 380 (M+, 5), 307 (70), 272 (30), 108 (100), 77 (50). Anal. Calcd for C19H16N4O3S (380.09): C, 59.99; H, 4.24; N, 14.73; S, 8.43. Found: C, 60.15; H, 4.42; N, 14.69; S, 8.63%.
Ethyl 5-[1-cyano-2-(1-methyl-1H-pyrrol-2-yl)-2-oxoethylidene)]-4-(4-methylphenyl)-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate (16g).
Yellow solid (0.35 g, 90%), mp 246 oC; IR (KBr) υ 2198 (C≡N), 1718, 1700 (2C=O) cm-1; 1H NMR (DMSO-d6) δ 1.35 (t, 3H, CH2CH3), 2.42 (s, 3H, Ar-CH3), 3.78 (s, 3H, N-CH3), 4.51 (q, 2H, CH2CH3), 7.12-7.87 (m, 7H, Ar-H) ppm; MS, m/z (%) 394 (M+, 15), 321 (40), 286 (30), 108 (100), 91 (20). Anal. Calcd for C20H18N4O3S (394.11): C, 60.90; H, 4.60; N, 14.20; S, 8.13. Found: C, 60.85; H, 4.40; N, 14.29; S, 8.23%.
5-[(1-Cyano-2-(1-methyl-1H-pyrrol-2-yl)-2-oxoethylidene)]-N,4-diphenyl-4,5-dihydro-1,3,4-thiadiazole-2-carboxamide (16h).
Yellow solid (0.39 g, 91%), mp 226 oC; IR (KBr) υ 2193 (C≡N), 1704, 1665 (2C=O) cm-1; 1H NMR (DMSO-d6) δ 3.49 (s, 3H, N-CH3), 7.14-8.16 (m, 13H, Ar-H), 11.14 (s, 1H, D2O exchangeable, NH) ppm; 13C NMR (DMSO-d6) δ 36.27, 65.81, 116.04, 119.33, 123.31, 126.17, 126.58, 127.88, 128.28, 129.19, 129.78, 130.54, 131.86, 133.42, 136.11, 156.77, 165.41, 168.19, 178.13 ppm; MS, m/z (%) 427 (M+, 40), 319 (40), 307 (50), 108 (10), 77 (30), 69 (100). Anal. Calcd for C23H17N5O2S (427.11): C, 64.62; H, 4.01; N, 16.38; S, 7.50. Found: C, 64.46; H, 4.12; N, 16.49; S, 7.39%.
Cytotoxic activity
Potential cytotoxicity of the compounds was tested using the method of Skehan et al.32 using Sulfo-Rhodamine-B stain (SRB). Cells were plated in 96-multiwill plates (104 cells/well) for 24 h before treatment with the tested compound to allow attachment of cell to the wall of the plate. Different concentrations of the compound under test (0, 1.56, 3.125, 6.25, 12.5, 25, and 50 µg/mL) were added to the cell monolayer in triplicate wells individual dose, monolayer cells were incubated with the compounds for 48 h at 37 °C and in atmosphere of 5% CO2. After 48 h, cells were fixed, washed and stained with SRB stain, excess stain was washed with acetic acid and attached stain was recovered with tris-EDTA buffer, color intensity was measured in an ELISA reader.
ACKNOWLEDGEMENTS
The support of this work was received from King Khalid University through research grant (KKU_S112_33).
References
1. G. S. Uscumlic, D. Z. Mijin, N. V. Valentic, V. V. Vajs, and B. M. Susic, Chem. Phys. Lett., 2004, 397, 148. CrossRef
2. Y. M. ElKholy and S. A. Abd El-Hafiz, Pigment Resin Technol., 1994, 23, 3. CrossRef
3. K. C. Chang, I. H. Su, G. H. Lee, and W. S. Chung, Tetrahedron Lett., 2007, 48, 7274. CrossRef
4. N. J. Wang, C. M. Sun, and W. S. Chung, Tetrahedron, 2011, 67, 8131. CrossRef
5. B. P. Patel, H. S. Patel, and P. J. Shah, Bulg. Chem. Commun., 2010, 42, 274.
6. H. Xu and X. Zeng, Bioorg. Med. Chem. Lett., 2010, 20, 4193. CrossRef
7. S. G. Kucukguzel, S. Rollas, H. Erdeniz, M. Kiraz, A. C. Ekinci, and A. Vidin, Eur. J. Med. Chem., 2000, 35, 761. CrossRef
8. T. A. Farghaly and M. M. Abdalla, Bioorg. Med. Chem., 2009, 17, 8012. CrossRef
9. D. J. Wilkins, “Comprehensive Heterocyclic Chemistry III”, Elsevier, Camelford, UK, 2008, p. 467. CrossRef
10. X. C. Wang, L. Zheng, Z. J. Quang, and D. J. Xu, Synth. Commun., 2003, 33, 2891. CrossRef
11. C. H. Oh, H. W. Cho, D. Baek, and J. H. Cho, Eur. J. Med. Chem., 2002, 37, 73. CrossRef
12. M. A. Ilies, D. Vullo, J. Pastorek, A. Scozzafava, M. Ilies, M. T. Caproiu, S. Pastorokova, and C. T. Supuran, J. Med. Chem., 2003, 46, 2187. CrossRef
13. M. Amir and K. Shikha, Eur. J. Med. Chem., 2004, 39, 535. CrossRef
14. N. Demirbas, A. S. Karaoglu, A. Demirbas, and K. Sancak, Eur. J. Med. Chem., 2004, 39, 793. CrossRef
15. K. D. Khalil, H. M. Al-Matar, D. M. Al-Dorri, and M. H. Elnagdi, Tetrahedron, 2009, 65, 9421. CrossRef
16. S. M. Gomha and K. D. Khalil, Molecules, 2012, 17, 9335. CrossRef
17. S. M. Gomha, S. M. Riyadh, I. M. Abbas, and M. A. Bauomi, Heterocycles, 2013, 87, 341. CrossRef
18. S. M. Riyadh and T. A. Farghaly, Tetrahedron, 2012, 68, 9056. CrossRef
19. H. M. Al-Matar, A. Y. Adam, K. D. Khalil, and M. H. Elnagdi, ARKIVOC, 2012, (vi), 1. CrossRef
20. R. Brehme, D. Enders, R. Fernandez, and J. M. Lassaletta, Eur. J. Org. Chem., 2007, 5629. CrossRef
21. J. G. Schantl and P. Hebeisen, Tetrahedron, 1990, 46, 395. CrossRef
22. E. O. M. Rufchahi and A. G. Gilani, Dyes Pigments, 2012, 95, 632. CrossRef
23. A. S. Shawali and M. A. El-Galil, Tetrahedron, 1971, 27, 4305. CrossRef
24. S. M. Riyadh, Molecules, 2011, 16, 1834. CrossRef
25. A. M. Farag, K. M. Dawood, and Z. E. Kandeel, Tetrahedron, 1996, 52, 7893. CrossRef
26. S. A. F. Rostom, I. M. El-Ashmawy, H. A. Abd El Razik, M. H. Badr, and H. M. A. Ashour, Bioorg. Med. Chem., 2009, 17, 882. CrossRef
27. M. A. A. Radwan, E. A. Ragab, N. M. Sabry, and S. M. El-Shenawy, Bioorg. Med. Chem., 2007, 15, 3832. CrossRef
28. A. El-Shafei, A. A. Fadda, A. M. Khalil, T. A. E. Ameen, and F. A. Badria, Bioorg. Med. Chem., 2009, 17, 5096. CrossRef
29. N. F. Eweiss and A. Osman, J. Heterocycl. Chem., 1980, 17, 1713. CrossRef
30. A. S. Shawali and A. O. Abdelhamid, Bull. Chem. Soc. Jpn., 1976, 49, 321. CrossRef
31. R. N. Butler, Chem. Rev., 1975, 75, 241. CrossRef
32. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. I. Warren, H. Bokesch, S. Kenney, and M. R. Boyd, J. Nat. Cancer Inst., 1990, 82, 1107. CrossRef